In the work by Zhang et al. the therapeutic effect of SGLT2 inhibitors (not specified) on the development of diabetic cardiomyopathy was studied in a rat model on a high-fat diet and with streptozotocin (STZ)-induced diabetes [219]. This evidence concerns the gene SLC5A2 and diabetic cardiomyopathy.